The current analysis was aimed to study the phytochemical profile and in vitro antidiabetic capacity of HEMC bark. HR-LCMS1 was used to identify the phytochemicals present in the extract. The outcomes of HR-LCMS showed the presence of 15 phytochemical compounds. DL-Carnitine, Catechin, D-α-Tocopherol, Colchicine, Myricetin, Epicatechin, Quercetin, Epigallocatechin gallate, Quercetin-3β-D-glucoside, Kaempferol, Sorbic acid, Apocynin, Epigallocatechin gallate, myricetin 3-O-beta-D-galactopyranoside, Naringeninchalcone are the main compounds identified. The inhibition of enzymes like α-amylase and α-glucosidase delays the rate of glucose absorption thus reducing blood glucose levels in the experimental models. The IC50 values of α-amylase and α-glucosidase inhibitory activity of HEMC were acquired to be 88.65 μg/mL and 71.28 μg/mL correspondingly. Positive control acarbose displayed IC50 assessment of 52.94 μg/mL and 50.01 μg/mL correspondingly. Consequently, the current study confirms that HEMC had remarkable antidiabetic activity and hence holds future potential as nutraceuticals in the treatment of diabetes and related ailments.
Keywords
